Funding for this research was provided by:
Eli Lilly and Company
Received: 13 March 2020
Accepted: 2 August 2020
First Online: 18 August 2020
Ethics approval and consent to participate
: This study was a post-hoc analysis of existing data from RA-BEGIN. The RA-BEGIN study was approved by each participating center’s institutional review board or ethics committee. All patients provided written informed consent.
: Not applicable.
: PLR, IT, and TH are all employees and shareholders of Eli Lilly and Company Ltd. LMG has declared no conflicts of interest. HB has received grant funding from FP7 HEALTH programme (Euro TEAM). EF has received advisory board and speaker fees from Novartis, Roche, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, and Sanofi.